Investors look for better efficacy from safe cancer immunotherapies
This article was originally published in Scrip
Company executives and biotech investors are very grateful for the way that Seattle-based Dendreon has paved the way for other cancer vaccines and immunotherapies. While it is still uncertain that the Provenge vaccine for metastatic castrate-resistant prostate cancer and its $93,000 price tag will ever be seen as a significant medical intervention or a commercial success, Dendreon's pioneering journey through both the technical and regulatory space is appreciated widely.
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.